Werewolf Therapeutics Inc (HOWL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Werewolf Therapeutics Inc (HOWL) has a cash flow conversion efficiency ratio of -0.512x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.16 Million) by net assets ($29.61 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Werewolf Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Werewolf Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read HOWL total liabilities for a breakdown of total debt and financial obligations.
Werewolf Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Werewolf Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RedCloud Holdings plc Ordinary Shares
NASDAQ:RCT
|
1.989x |
|
US Energy Corp
NASDAQ:USEG
|
-0.006x |
|
WPP PLC
LSE:WPP
|
-0.304x |
|
G11 Resources Ltd
AU:G11
|
-0.046x |
|
INmune Bio Inc
NASDAQ:INMB
|
-0.214x |
|
Culp, Inc. Common Stock
NYSE:CULP
|
-0.022x |
|
Display Tech Co. Ltd
KQ:066670
|
0.068x |
|
Dabomb Protein
TWO:6578
|
-0.013x |
Annual Cash Flow Conversion Efficiency for Werewolf Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Werewolf Therapeutics Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see HOWL company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $73.39 Million | $-56.19 Million | -0.766x | -161.46% |
| 2023-12-31 | $111.37 Million | $-32.61 Million | -0.293x | +11.76% |
| 2022-12-31 | $122.34 Million | $-40.60 Million | -0.332x | -18.25% |
| 2021-12-31 | $152.79 Million | $-42.88 Million | -0.281x | -34.43% |
| 2020-12-31 | $89.22 Million | $-18.62 Million | -0.209x | +78.63% |
| 2019-12-31 | $9.77 Million | $-9.54 Million | -0.977x | -- |
About Werewolf Therapeutics Inc
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies throu… Read more